| ROCHE HLDG AG GEN. | 239.60 / +0.74% |
| Date/Time | 03/21 / 17:05 |
| Chg. / Chg.(%) | 1.75 / +0.74% |
| Bid | - |
| Ask | - |
| Open | 240.00 |
| Previous Close | 237.85 |
| High | 240.00 |
| Low | 238.30 |
| Volume [EUR] | 1,200.00 |
| Volume [Units] | 5 |
| Price fixings | 5 |
| ISIN | CH0012032048 |
| Security | RHO5 |
| Exchange | Düsseldorf |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| SIX Swiss Ex.. | 270.65 |  |
1,157,223 |
| London Inter.. | 270.15 | |
379,057 |
| Cboe Europe .. | 270.15 | |
86,485 |
| Turquoise | 270.15 | |
67,926 |
| Xetra | 236.95 | |
2,896 |
| Frankfurt | 239.600 | |
2,040 |
| TradeGate | 239.950 | |
1,356 |
| Nasdaq Other.. | 271.0000 |  |
489 |
| Stuttgart | 239.350 | |
440 |
| Borsa Italia.. | 238.00 | |
50 |
| Düsseldorf | 239.60 | |
5 |
| Berlin | 238.75 | |
0 |
| München | 238.60 | |
0 |
| Hamburg | 238.50 | |
0 |
| Lang & Schwa.. | 239.431 | |
|
| gettex | 239.750 | |
|
| Mexico | 5,220.00 | 256 | |
| Mexico | 4,744.44 | 32 | |
| Borsa Italia.. | 238.00 | ||
| EUREX | Options | ||
News
- Biopharmaceuticals Market Analysis & Outlook, 2019 to 2024 - Their Ability to Treat Previously Untreatable Diseases is Spurring Growth
03/20/2019 / 12:40 - GlobeNewswire - FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
03/19/2019 / 07:00 - GlobeNewswire - European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease
03/15/2019 / 07:00 - GlobeNewswire - European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors
03/14/2019 / 07:00 - GlobeNewswire - Roche's VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
03/11/2019 / 07:03 - GlobeNewswire
Real-time